|
显示项目 539221-539230 / 2346275 (共234628页)
<< < 53918 53919 53920 53921 53922 53923 53924 53925 53926 53927 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; JAU-YU LIAU; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T09:22:43Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin, Yu-Lin;Liau, Jau-Yu;Yu, Shan-Chi;Ou, Da-Liang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Y.-L. and Liau, J.-Y. and Yu, S.-C. and Ou, D.-L. and Lin, L.-I. and Tseng, L.-H. and Chang, Y.-L. and Yeh, K.-H. and Cheng, A.-L.; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; Lin, Yu-Lin; LI-HUI TSENG; Lin, Yu-Lin; Liau, Jau-Yu; YIH-LEONG CHANG; JAU-YU LIAU; Yu, Shan-Chi; Ou, Da-Liang; DA-LIANG OU; Ou, Da-Liang; LIANG-IN LIN; Lin, Liang-In; Lin, Liang-In; Tseng, Li-Hui; KUN-HUEI YEH; Tseng, Li-Hui; Chang, Yih-Leong; YU-LIN LIN; Yeh, Kun-Huei; ANN-LII CHENG; Yeh, Kun-Huei; Cheng, Ann-Lii; Cheng, Ann-Lii; Cheng, Ann-Lii |
| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Yeh K.-H.; Cheng A.-L.; YIH-LEONG CHANG; Lin L.-I.; Tseng L.-H.; Yu S.-C.; Ou D.-L.; Liau J.-Y.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Liau J.-Y.; SHAN-CHI YU; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
| 國立成功大學 |
2013-05-20 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, Li-Tzong; Chen, Jen-Shi; Chao, Yee; Tsai, Chang-Sung; Shan, Yan-Shen; Hsu, Chiun; Huang, Shiu-Feng; Tsou, Hsiao-Hui; Lee, Kuan-Der; Chiu, Chang-Fang; Rau, Kun-Ming; Ho, Ching-Liang; Yu, Ming-Sun |
| 國立臺灣大學 |
2014 |
KRAS 基因突變增加oxaliplatin化學治療藥物敏感性對轉移性結腸直腸癌的生物意義與臨床影響
|
林育麟; Lin, Yu-Lin |
| 亞洲大學 |
1999 |
Krashen 之第二語言習得理論及其對台灣國小英語教學之啟示
|
張湘君 |
| 國立臺灣師範大學 |
2014-10-27T15:12:35Z |
Krashen's Five Hypotheses and their Implications
|
張進生 |
显示项目 539221-539230 / 2346275 (共234628页)
<< < 53918 53919 53920 53921 53922 53923 53924 53925 53926 53927 > >>
每页显示[10|25|50]项目
|
